CEL-SCI CORP (CVM) Stock Price, Forecast & Analysis

Can you describe the business of CEL-SCI CORP?

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

What is the current price of CVM stock?

The current stock price of CVM is 6.32 USD. The price increased by 5.33% in the last trading session.

What is the dividend status of CEL-SCI CORP?

CVM does not pay a dividend.

What is the ChartMill technical and fundamental rating of CVM stock?

CVM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.

What is the analyst forecast for CVM stock?

5 analysts have analysed CVM and the average price target is 306 USD. This implies a price increase of 4741.77% is expected in the next year compared to the current price of 6.32.

How many employees does CEL-SCI CORP have?

CEL-SCI CORP (CVM) currently has 0 employees.